NCT06511882View on ClinicalTrials.gov

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

PHASE2RecruitingINTERVENTIONAL

Enrollment

37

Participants

Timeline

Start Date

November 7, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2028

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Azacitidine

Standard of Care Intravenous (IV) infusion

DRUG

Decitabine

Standard of Care Intravenous (IV) infusion

DRUG

Venetoclax

Standard of Care PO (By Mouth)

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AbbVie

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER